Second Genome is at the cutting edge of microbiome science, translating breakthrough research into medicines and other novel products that help humanity.
Our scientists and staff are true pioneers in this dynamic field. We are advancing a pipeline of novel therapies for serious diseases, while also making new breakthroughs in multiple fields of research using our one-of-a kind discovery platform. With our impact felt across industries — from healthcare and nutrition to agriculture — we are recognized as global leaders in translating rapidly emerging science into products that help humanity.
Second Genome’s culture of excellence also makes us the expert-partner of choice for exciting microbiome research projects with leading corporations, academic institutions and government.
While we are driven by science, it is our people who are at the core of our success. We are committed to hiring top talent, rewarding our employees and creating an atmosphere that fosters creativity and continued growth.
Our scientists and staff are true pioneers in this dynamic field. We are advancing a pipeline of novel therapies for serious diseases, while also making new breakthroughs in multiple fields of research using our one-of-a kind discovery platform. With our impact felt across industries — from healthcare and nutrition to agriculture — we are recognized as global leaders in translating rapidly emerging science into products that help humanity.
Second Genome’s culture of excellence also makes us the expert-partner of choice for exciting microbiome research projects with leading corporations, academic institutions and government.
While we are driven by science, it is our people who are at the core of our success. We are committed to hiring top talent, rewarding our employees and creating an atmosphere that fosters creativity and continued growth.
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $56M
Founded date: 2009
Investors 4
| Date | Name | Website |
| - | Digitalis ... | digitalisv... |
| - | Lifeforce ... | lifeforcec... |
| - | Lightstone... | lightstone... |
| - | SR One | srone.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 13.07.2016 | Series B | $8.4M | - |
| 21.04.2016 | Series B | $42.6M | - |
| 10.08.2011 | Series A | $5M | - |
Mentions in press and media 17
| Date | Title | Description |
| 17.04.2019 | As researchers pursue links between bacteria and human health, startups stand to benefit | In 2009, the National Institutes of Health launched a five-year, $150 million project to stimulate research into a new field of medicine examining the connections between the millions of bacteria living in the human gut and overall human he... |
| 17.04.2019 | Salesforce CEO Marc Benioff invests in $25M round for Naveen Jain’s microbiome startup Viome | (Viome Photo) Viome, a wellness startup from entrepreneur Naveen Jain, has raised $25 million in funding from a crop of investors that includes Salesforce CEO Marc Benioff. Jain said the new cash, which brings the Seattle-area startup’s tot... |
| 04.01.2019 | Up to $818 million deal between J&J and Locus Biosciences points to a new path for CRISPR therapies | The up to $818 million deal between Locus Biosciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) that was announced yesterday points toward a new path for CRISPR gene editing technologies and (potentially) the whole f... |
| 30.01.2018 | 5 projects using AI to combat global inequality | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today! Artificial intelligence promises to improve human... |
| 30.11.2016 | Axial Biotherapeutics raises $19.15M to target gut-brain axis | This builds on an array of preclinical research that has shown a link between gut bacteria and neurological conditions such as autism spectrum disorders (ASD) and Parkinson’s Disease. The field has received a lot of buzz in recent years, bu... |
| 13.07.2016 | Biopharmaceutical Company Second Genome Raises $8.4M in Series B Financing | Second Genome, a South San Francisco, California-based biopharmaceutical company, raised $8.4m in Series B financing. SR One made – the corporate venture capital arm of GlaxoSmithKline – the investment, which brought the total Series B fund... |
| 21.04.2016 | Second Genome Closes $42.6M Series B Funding | Second Genome, Inc., a South San Francisco, CA-based biopharmaceutical company developing novel medicines through innovative microbiome science, closed a $42.6m Series B funding. The round was co-led by Pfizer Venture Investments and Roche ... |
| 09.06.2014 | Seres Health adds Mayo Clinic in $10M series B to advance microbiome therapeutics | The level of interest in the microbiome has been compared to genomics. It’s a an area of growing investment as scientists increasingly see connections between microbes and a wide range of conditions. Other biotech companies in the microbiom... |
| 07.05.2014 | Pfizer joins the microbiome movement, enlisting Second Genome for obesity study | In an effort to better understand the relationship between the microbiome, obesity and metabolic disorders, they’ll study about 900 obese individuals selected by a team at Massachusetts General Hospital over 12 months. In addition to lookin... |
| 26.12.2013 | 5 biotech startups braving the new world of microbiome therapies | Drug discovery firm Second Genome, founded in 2010, raised an $11.5 million Series A round this year and secured a deal with Janssen to advance new microbiome-based therapies for ulcerative colitis. In its own pipeline, the company says it’... |
Show more